Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options.

2 Jun 2016

Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit.

24 May 2016

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility of tumor cell-free DNA as a predictor of therapeutic response to immunotherapy after the first cycle of treatment in eight different types of cancer.

20 May 2016

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

16 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. The study was published in the journal Molecular Cancer Therapeutics.

3 May 2016

Study identifies genetic differences in kidney tumors of African-Americans

A University of North Carolina Lineberger Comprehensive Cancer Center-led study has identified genetic differences in tumors of African-Americans with the most common type of kidney cancer compared with whites.

26 Mar 2016

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

A research team of the Comprehensive Cancer Center of MedUni Vienna and AKH Vienna was able to demonstrate that a therapy change in the area of metastasising renal cell carcinoma significantly increases the life average expectancy and clearly improves the compatibility of the therapy.

9 Mar 2016

Robotic nephrectomy for inferior vena cava tumor thrombus shows promise in selected patients

Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, report surgeons in The Journal of Urology.

8 Feb 2016

Duke researchers identify promising target for renal cell carcinomas

All cells need nutrients, but cancer cells are notoriously power hungry. As a result, cancer cells must alter their metabolism to provide the additional fuel needed for them to survive, grow and spread.

4 Feb 2016

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics.

22 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine.

11 Jan 2016

HealthWell Foundation opens new fund to provide financial assistance to Medicare patients suffering from RCC

The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, today announced it has opened a new fund to provide financial assistance to Medicare patients suffering from renal cell carcinoma (RCC).

31 Dec 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

Rutgers research reveals mechanism to prevent benign kidney tumor from becoming cancerous

Research from investigators at Rutgers Cancer Institute of New Jersey examining the inner workings of a rare non-cancerous (benign) kidney tumor has revealed a mechanism to prevent this type of tumor from becoming cancerous (malignant).

22 Nov 2015

Meat-rich diet may increase kidney cancer risk

A new study indicates that a meat-rich diet may increase the risk of developing kidney cancer through mechanisms related to particular cooking compounds. Also, these associations may be modified by genetic susceptibility to kidney cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study illustrates how diet and genetics may interact to impact cancer risk.

10 Nov 2015

Brain metastases evolve ‘clinically actionable’ mutations

Brain metastatic disease shows branched evolution from the primary tumour, suggest preliminary findings from the largest massively parallel sequencing study of paired samples performed so far.

7 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Bayer-new phase 3 liver cancer data

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Study identifies genetic differences in kidney tumors of African-Americans

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

Robotic nephrectomy for inferior vena cava tumor thrombus shows promise in selected patients

Duke researchers identify promising target for renal cell carcinomas

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

PD-L1 inhibition well-tolerated, active in metastatic RCC

CTCA at Western announces launch of Phase II NivoPlus clinical trial

HealthWell Foundation opens new fund to provide financial assistance to Medicare patients suffering from RCC

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Rutgers research reveals mechanism to prevent benign kidney tumor from becoming cancerous

Meat-rich diet may increase kidney cancer risk

Brain metastases evolve ‘clinically actionable’ mutations

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

New drug works better than current treatments for advanced kidney cancer

Free guide - everything about renal proximal tubule cells eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Free guide - everything about renal proximal tubule cells eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in